Press Releases for ALKS

Press Releases
Analyst Choice Updated Analysis on DENTSPLY International Inc., PAETEC Holding Corp., Antigenics Inc., Cubist Pharmaceuticals Inc., Alkermes Inc. and Biogen Idec Inc.
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on ALV, CLS, VIT, TKC, CRK and ALKS
Alkermes Reports First Quarter Fiscal 2010 Financial Results
Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010
Alkermes’ Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
BenchmarkJournal.Com Free Analyst Review for ITUB, APWR, CHRS, FMBI, ALKS and HANS
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus® in Head-to-Head DURATION-3 Study
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare Conference
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Investor Conferences
Alkermes Reports Financial Results for Fiscal 2009 and Provides Financial Expectations for Fiscal 2010
FDA Grants Approval for Use of RISPERDAL® CONSTA® as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Alkermes to Host Conference Call to Discuss Fiscal Year 2009 Financial Results
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 34th Annual Health Care Conference
Alkermes Initiates Two New Clinical Trials Of ALKS 33
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Investor Conferences
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
RISPERDAL® CONSTA® Approved in Japan
Alkermes Completes Enrollment for Registration Study of VIVITROL® in Patients with Opioid Dependence
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 12:57PM
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 6:55AM
Alkermes Highlights Advancing Proprietary Product Portfolio at R&D Day
Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
WallStSense.Com Initiates Free Ratings Report on PBCT, AMLN, ALKS and ATHR... Sign Up Now
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Alkermes to Webcast R&D Day on Tuesday, April 7, 2009
Alkermes Announces Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
FDA Issues Complete Response Letter for RISPERDAL® CONSTA® for Adjunctive Maintenance Treatment of Bipolar Disorder
Alkermes’ Corporate Presentation to be Webcast at the 21st Annual Roth OC Growth Stock Conference
Zacks Bull & Bear of the Day Highlights: Sohu.Com, Alkermes, ViroPharma, Sanderson Farms and Nordstrom
Zacks Analyst Blog Highlights: Alkermes, Cephalon, Drugstore.Com, Inc., Vivo ParticipaÃ§ÃµEs S.A. And Telemig
Alkermes Announces Third Quarter Fiscal 2009 Results
Research and Markets: The Acquisition of Serono Fulfills, In Part, Merck Group Plans To Increase Its Pharma Presence in the US - Feb 4 2009 11:57PM
Research and Markets: The Acquisition of Serono Fulfills, In Part, Merck Group Plans To Increase Its Pharma Presence in the US - Feb 4 2009 12:00PM
Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2009
Alkermes Announces Initiation of First Clinical Study for a Four-Week Long-Acting Injectable Formulation of Risperidone
Alkermes’ Corporate Presentation to be Webcast at JPMorgan Annual Healthcare Conference
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other CNS Disorders
Alkermes Regains Full Commercialization Rights to VIVITROL® in US
Alkermes’ Corporate Presentation to be Webcast at JPMorgan SMid Cap Conference
Alkermes’ Corporate Presentation to be Webcast at the NASDAQ Investor Program
Alkermes Presents Positive Preclinical Data on Novel, Proprietary Molecule Designed to Improve Outcomes for Patients Taking Opioid Analgesics
Alkermes' Corporate Presentation to be Webcast at Lazard Capital Markets Fifth Annual Healthcare Conference
Alkermes Announces Second Quarter Fiscal 2009 Results
Zacks Analyst Blog Highlights: Alkermes, Inc., Eli Lilly & Co., The Ryland Group, Epicor Software Corp. And Synopsys Inc.
Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2009
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
David Anstice Elected to Alkermes' Board of Directors
Alkermes' Corporate Presentation to be Webcast at the UBS Global Life Sciences Conference
Alkermes' Corporate Presentation to be Webcast at Two Upcoming Investor Conferences
Alkermes' Corporate Presentation to be Webcast at the Thomas Weisel Partners Healthcare Conference
Alkermes Announces First Quarter Fiscal 2009 Results and Raises Financial Expectations for Fiscal 2009
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2009
Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Bipolar Disorder
Alkermes Presents Positive Preclinical Data on Naltrexone for Extended-Release Injectable Suspension at Annual Meeting of Controlled Release Society
Alkermes Presents Positive Data on Proprietary Molecules Targeting Opioid Receptors
Alkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid Dependence - Jun 26 2008 8:49AM
Alkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid Dependence - Jun 26 2008 8:48AM
Alkermes Expands Common Stock Repurchase Program and Raises Fiscal Year 2009 Financial Expectations
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
Alkermes' Corporate Presentation to be Webcast at the Friedman, Billings, Ramsey Spring Investor Conference
BellwetherReport.com Analyst Report on AAPL, PSUN, ALKS and VRGY - May 27 2008 1:03AM
Alkermes Reports Financial Results for Fiscal 2008 and Provides Financial Expectations for Fiscal 2009 - May 26 2008 10:31PM
Alkermes to Host Conference Call to Discuss Fiscal Year 2008 Financial Results - May 27 2008 12:54AM
Alkermes' Corporate Presentation to be Webcast at the Bank of America Securities Health Care Conference - Jun 1 2008 7:07AM
Alkermes' Corporate Presentation to Be Webcast at the Morgan Stanley Global Healthcare Unplugged Conference
Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Frequently Relapsing Bipolar Disorder